![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Publication history |
Estratti |
Permessi |
Per citare questo articolo |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEW
Minerva Respiratory Medicine 2021 December;60(4):136-41
DOI: 10.23736/S2784-8477.21.01921-0
Copyright © 2021 EDIZIONI MINERVA MEDICA
lingua: Inglese
COVID-19 vaccines: challenges and solutions
Zeinab MOHSENI AFSHAR 1, Arefeh BABAZADEH 2, Alireza JANBAKHSH 1, Mandana AFSHARIAN 1, Soheil EBRAHIMPOUR 2 ✉
1 Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2 Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a global emergency by the World Health Organization (WHO). Several ways have been used to control and manage the COVID-19 pandemic. Among them, development of vaccines could be an important breakthrough against novel virus. It is important to note that the candidate vaccine is expected to work against infection and transmission. To date, many COVID-19 vaccine clinical trials have been registered worldwide. However, some vaccine candidates could meet adequate standards for effectiveness and safety. In the current review, we discussed the effectiveness, safety, target population, and hesitancy of COVID-19 vaccines.
KEY WORDS: SARS-CoV-2; COVID-19; Vaccines